Target intelligence / Profile preview

Mitochondrially encoded ATP synthase membrane subunit 8 (MT-ATP8)

Target
MT-ATP8
Molecular classification
Enzyme subunit, Mitochondrial membrane protein, Other (Component of ATP synthase/Complex V, not a standalone catalytic enzyme)
01

Overview

Mitochondrially encoded ATP synthase membrane subunit 8 (MT-ATP8) is a small subunit of the F₀ portion of ATP synthase (Complex V) in the inner mitochondrial membrane. This essential enzyme complex generates ATP, the main cellular energy molecule, by coupling ADP phosphorylation to proton flow produced by the mitochondrial electron transport chain. MT-ATP8 is encoded by mitochondrial DNA and is not itself catalytically active, but is believed to stabilize and structurally organize the F₀ membrane domain, anchoring the stator to prevent futile rotation as protons translocate. Mutations in MT-ATP8 are implicated in diverse mitochondrial disorders, including hypertrophic cardiomyopathy, Leigh syndrome, and other multi-system diseases. There are no approved drugs specifically targeting this subunit, and inhibition of ATP synthase by agents such as oligomycin can have severe cytotoxic consequences due to abrogated energy production.

Other names
ATP synthase F₀ complex subunit 8ATP synthase subunit 8ATP8ATPASE8MTATP8A6LURFA6LF-ATPase subunit 8Mitochondrially encoded ATP synthase membrane subunit A6L
02

Mechanism of action

None established as there are no drugs specifically targeting this subunit. Drugs such as oligomycin inhibit the F₀ complex as a whole, blocking proton flow and ATP synthesis.

03

Biological functions

ATP synthesis during oxidative phosphorylationMitochondrial energy productionProton transmembrane transport (as part of the larger complex)
04

Disease associations

Mitochondrial disease (e.g., neonatal mitochondrial encephalomyopathy)Cardiomyopathy, infantile hypertrophicNeuropathy, ataxia, and retinitis pigmentosaMultiple sclerosisUrinary bladder cancer
05

Safety considerations

Targeting MT-ATP8/ATP synthase risks inhibiting cellular energy production, leading to cellular dysfunction or death; severe consequences associated with loss-of-function mutations in humans, including cardiomyopathy and multi-system mitochondrial disorders.
06

Interacting drugs

None directly; no approved drugs specifically target MT-ATP8

1 more in the full profile.

07

Biomarkers

MT-ATP8 gene mutations can serve as biomarkers for certain mitochondrial diseases, particularly those involving cardiomyopathy and neuromuscular symptoms.

Beyond the preview

Go deeper on Mitochondrially encoded ATP synthase membrane subunit 8 (MT-ATP8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrially encoded ATP synthase membrane subunit 8 (MT-ATP8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call